Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

AAV-Follistatin Gene Therapy Targeting Neuromuscular Diseases with Weakness and Atrophy of the Quadriceps Muscle
Neurogenetics and Gene Therapy
(-)
110
Authors/Disclosures
Janaiah Kota (The Research Institute at Nationwide Children) No disclosure on file
No disclosure on file
Saqib A. Chaudhry, MD Dr. Chaudhry has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Louise R. Rodino-Klapac (Sarepta Therapeutics) Ms. Rodino-Klapac has received personal compensation for serving as an employee of Sarepta Therapeutics, Inc.. Ms. Rodino-Klapac has received stock or an ownership interest from Sarepta Therapeutics. Ms. Rodino-Klapac has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
No disclosure on file
No disclosure on file
Christopher Shilling, MS (Nationwide Children'S Hospital) No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
K. Reed Clark, PhD No disclosure on file
Zarife F. Sahenk, MD, PhD, FÂé¶¹´«Ã½Ó³»­ (The Research Institute at Nationwide Childrens.org) Dr. Sahenk has nothing to disclose.
Jerry R. Mendell, MD, FÂé¶¹´«Ã½Ó³»­ (The Research Institute at Nationwide Children's Hospital) Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vertex. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta Therapeutics . The institution of Dr. Mendell has received research support from Sarepta.
Brian K. Kaspar, PhD No disclosure on file